Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Procter & Gamble Company    PG

PROCTER & GAMBLE COMPANY

(PG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Myriad Submits sPMA for BRACAnalysis CDx Test

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/21/2020 | 07:44am EST

By Michael Dabaie

Myriad Genetics said it submitted a supplementary premarket approval application to the U.S. Food and Drug Administration.

The sPMA is for the company's BRACAnalysis CDx test as a companion diagnostic to AstraZeneca and Merck & Co.'s (MRK) Lynparza for men with metastatic castration-resistant prostate cancer.

AstraZeneca and Merck said Tuesday the supplemental New Drug Application for Lynparza was been accepted and granted priority review by the FDA.

Myriad said the filing for BRACAnalysis CDx is based on the positive clinical results from the PROfound study.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -1.66% 7708 Delayed Quote.3.02%
MERCK AND COMPANY -0.23% 90.97 Delayed Quote.0.02%
MERCK KGAA 0.26% 116.5 Delayed Quote.10.39%
MRK HOLDINGS INC. 4.05% 257 End-of-day quote.15.25%
MYRIAD GENETICS, INC. -0.69% 28.72 Delayed Quote.5.47%
PROCTER & GAMBLE COMPANY 0.27% 126.41 Delayed Quote.1.21%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROCTER & GAMBLE COMPANY
07:44aMyriad Submits sPMA for BRACAnalysis CDx Test
DJ
07:29aAstraZeneca, Merck Get FDA Priority Review for Lynparza in Form of Prostate C..
DJ
01/20PROCTER & GAMBLE COMPANY : half-yearly earnings release
01/20PROCTER & GAMBLE : New Dawn Powerwash Dish Spray; Award-Winning Chef Curtis Ston..
AQ
01/18Drugmakers slash prices to be eligible for China's bulk-buy program
RE
01/17PROCTER & GAMBLE : Clean as You Go Like a Pro With New Dawn PowerwashTM Dish Spr..
BU
01/16Nestlé Unwraps New Initiative to Cut Plastic Waste
DJ
01/14PROCTER & GAMBLE CO : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
01/14PROCTER & GAMBLE : P&G Declares Quarterly Dividend
BU
01/14KIMBERLY CLARK : The global baby diapers market at a cagr of over 5% during the ..
AQ
More news
Financials (USD)
Sales 2020 70 670 M
EBIT 2020 15 643 M
Net income 2020 12 895 M
Debt 2020 20 610 M
Yield 2020 2,38%
P/E ratio 2020 25,8x
P/E ratio 2021 24,2x
EV / Sales2020 4,75x
EV / Sales2021 4,58x
Capitalization 315 B
Chart PROCTER & GAMBLE COMPANY
Duration : Period :
Procter & Gamble Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROCTER & GAMBLE COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 133,86  $
Last Close Price 126,41  $
Spread / Highest target 89,9%
Spread / Average Target 5,89%
Spread / Lowest Target -16,1%
EPS Revisions
Managers
NameTitle
David S. Taylor Chairman, President & Chief Executive Officer
Jon R. Moeller Vice Chairman, Chief Operating & Financial Officer
Kathleen B. Fish Chief Research, Development & Innovation Officer
Javier Polit Chief Information Officer
Scott D. Cook Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PROCTER & GAMBLE COMPANY1.21%315 243
UNILEVER N.V.-0.37%145 442
THE ESTÉE LAUDER COMPANIES INC.6.46%79 116
HINDUSTAN UNILEVER LTD6.14%62 853
COLGATE-PALMOLIVE COMPANY3.40%61 004
RECKITT BENCKISER GROUP PLC0.07%56 586